FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562912637> ?p ?o ?g. }

• W2562912637 endingPage "180" @default.
• W2562912637 startingPage "180" @default.
• W2562912637 abstract "Abstract According to the IMWG criteria, evaluation of response in multiple myeloma (MM) is based on the measurement of the monoclonal protein in serum and/or urine. In patients secreting only light chains (LCMM), evaluation is based on the urine electrophoresis, and measurable disease is defined by the presence of > 200 mg/24h light chains in the urine. This definition and recommendation has several pitfalls. It is difficult to be sure that the 24 hours urines collection is complete, especially in elderly patients. Even if complete, evaluation of response is difficult, and may not reflect the response at the plasma cell level. Indeed, light chains are usually very rapidly cleared, and patients are in complete response (CR) after only a couple of chemotherapy courses. For now more than 10 years, free light chains can be measured in the serum (sFLC) using the Freelite® kit (The Binding Site, Birmingham, UK). We took advantage of the large cohort of patients enrolled in the IFM/DFCI 2009 trial (700 patients) to address the question of the usefulness of Freelite® in evaluating response. The IFM/DFCI trial enrolled 700 patients in the IFM from 11/2010 to 12/2012. The trial randomized patients between arm A, 8 RVD courses, and arm B, 3 VRD courses, high-dose melphalan, 2 VRD courses. All patients did receive a one-year lenalidomide maintenance. We identified 115 patients (16.4 %) with LCMM, all patients presented with an abnormal sFLC ration and had measurable disease (>100mg/L) as described by the IMWG. All the patients were centrally evaluated for response at the end of the induction (3 VRD courses) with urine electrophoresis and serum FLC at this time, urine electrophoreses were negative in 88/112 patients (79%, 3 patients not evaluated). Based on sFLC evaluation, a normal ratio and/or normal kappa and lambda levels was observed in 58/112 patients (52%). Of note, the discordances were always in the group of patients with normal electrophoresis and abnormal FLC. In order to evaluate the speed of response on urine electrophoresis, we tried to collect the results performed locally in each IFM center after only one cycle of VRD. Data were available for 84 patients, 52 (62%) already presenting a normal electrophoresis. Finally, in order to verify that the response assessment by Freelite® was comparable to that observed in classical MM (IgG and IgA), we analyzed those patients who did present at diagnosis a sFLC excretion, as defined by > 100 mg/L. We did identify 331/585 patients in this case. Among them, 65/70 patients in nCR or CR presented a normal sFLC ratio and/or normal kappa and lambda levels. For patients in VGPR, 98/120 displayed a normal Freelite®. For patients in PR or less, only 29/141 presented normal Freelite®. Based on Freelite®, 58% of these classical MM presented a normal sFLC ration and individual FLC levels not statistically different from the 52% observed in LCMM. In conclusion, we confirm here that response evaluation based on urine electrophoresis is not reliable because of a very rapid clearance of the LC in urines. In contrast, sFLC assessment is much more reliable, with response evaluations statistically similar to that observed in classical IgG or IgA MM. We propose to reevaluate the IMWG response criteria for LCMM incorporating the serum FLC assessments Disclosures No relevant conflicts of interest to declare." @default.
• W2562912637 created "2017-01-06" @default.
• W2562912637 creator A5009878725 @default.
• W2562912637 creator A5021139263 @default.
• W2562912637 creator A5023937847 @default.
• W2562912637 creator A5030565933 @default.
• W2562912637 creator A5063422967 @default.
• W2562912637 creator A5069449708 @default.
• W2562912637 date "2014-12-06" @default.
• W2562912637 modified "2023-09-26" @default.
• W2562912637 title "Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial" @default.
• W2562912637 doi "https://doi.org/10.1182/blood.v124.21.180.180" @default.
• W2562912637 hasPublicationYear "2014" @default.
• W2562912637 type Work @default.
• W2562912637 sameAs 2562912637 @default.
• W2562912637 citedByCount "1" @default.
• W2562912637 countsByYear W25629126372018 @default.
• W2562912637 crossrefType "journal-article" @default.
• W2562912637 hasAuthorship W2562912637A5009878725 @default.
• W2562912637 hasAuthorship W2562912637A5021139263 @default.
• W2562912637 hasAuthorship W2562912637A5023937847 @default.
• W2562912637 hasAuthorship W2562912637A5030565933 @default.
• W2562912637 hasAuthorship W2562912637A5063422967 @default.
• W2562912637 hasAuthorship W2562912637A5069449708 @default.
• W2562912637 hasConcept C126322002 @default.
• W2562912637 hasConcept C141071460 @default.
• W2562912637 hasConcept C143998085 @default.
• W2562912637 hasConcept C159654299 @default.
• W2562912637 hasConcept C203014093 @default.
• W2562912637 hasConcept C2776063141 @default.
• W2562912637 hasConcept C2776364478 @default.
• W2562912637 hasConcept C2778684742 @default.
• W2562912637 hasConcept C36394416 @default.
• W2562912637 hasConcept C71924100 @default.
• W2562912637 hasConcept C72563966 @default.
• W2562912637 hasConcept C90924648 @default.
• W2562912637 hasConceptScore W2562912637C126322002 @default.
• W2562912637 hasConceptScore W2562912637C141071460 @default.
• W2562912637 hasConceptScore W2562912637C143998085 @default.
• W2562912637 hasConceptScore W2562912637C159654299 @default.
• W2562912637 hasConceptScore W2562912637C203014093 @default.
• W2562912637 hasConceptScore W2562912637C2776063141 @default.
• W2562912637 hasConceptScore W2562912637C2776364478 @default.
• W2562912637 hasConceptScore W2562912637C2778684742 @default.
• W2562912637 hasConceptScore W2562912637C36394416 @default.
• W2562912637 hasConceptScore W2562912637C71924100 @default.
• W2562912637 hasConceptScore W2562912637C72563966 @default.
• W2562912637 hasConceptScore W2562912637C90924648 @default.
• W2562912637 hasIssue "21" @default.
• W2562912637 hasLocation W25629126371 @default.
• W2562912637 hasOpenAccess W2562912637 @default.
• W2562912637 hasPrimaryLocation W25629126371 @default.
• W2562912637 hasRelatedWork W2003715807 @default.
• W2562912637 hasRelatedWork W2025081120 @default.
• W2562912637 hasRelatedWork W2136773918 @default.
• W2562912637 hasRelatedWork W2344741804 @default.
• W2562912637 hasRelatedWork W2509347433 @default.
• W2562912637 hasRelatedWork W2605951469 @default.
• W2562912637 hasRelatedWork W4238487952 @default.
• W2562912637 hasRelatedWork W4256097116 @default.
• W2562912637 hasRelatedWork W4280514659 @default.
• W2562912637 hasRelatedWork W4301898288 @default.
• W2562912637 hasVolume "124" @default.
• W2562912637 isParatext "false" @default.
• W2562912637 isRetracted "false" @default.
• W2562912637 magId "2562912637" @default.
• W2562912637 workType "article" @default.